Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc. Frequently Asked Questions
What is the ticker symbol for Acurx Pharmaceuticals, Inc.? What does ACXP stand for in stocks?
ACXP is the stock ticker symbol of Acurx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Acurx Pharmaceuticals, Inc. (ACXP)?
As of Wed Nov 20 2024, market cap of Acurx Pharmaceuticals, Inc. is 23.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ACXP stock?
You can check ACXP's fair value in chart for subscribers.
Is Acurx Pharmaceuticals, Inc. a good stock to buy?
The fair value guage provides a quick view whether ACXP is over valued or under valued. Whether Acurx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Acurx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACXP.